Bob Crutchfield manages BrightEdge Ventures, the American Cancer Society’s strategic venture philanthropy platform. His work with BrightEdge targets investments that advance the commercialization of advanced therapies to treat, detect and prevent all types of cancer.
Prior to the BrightEdge Fund, Crutchfield was executive director of Innovate Birmingham, an 18-month initiative in which he led a team to assess, evaluate and recommend strategies to accelerate growth of that market’s technology-based economy to Birmingham’s economic development organizations. During this time, he also served as an operating advisor to Harbert Growth Partners, after stepping down as senior partner and healthcare practice leader in 2017.
The investments that have been realized while Crutchfield served as a board member or board observer include Shipt, (acquired by Target in 2017); Wellcentive, (acquired by Royal Philips in 2016); nContact, (acquired by Atricure in 2014); and Novamin (acquired by GSK in 2009).
Prior to Harbert, Crutchfield was the founder and CEO of Surgical Innovations & Services, Inc. (SIS). Under his leadership, SIS became a leader in the emerging outsource management sector, with over 300 hospitals and surgery centers under contract. He went on to become vice president and general manager of the Pharmacy Services Division at US Oncology, a privately held, vertically integrated cancer care provider network that was sold to McKesson in 2010.
Crutchfield also serves on the boards of the Southeastern Medical Device Association, the Southern Capital Forum, the Innovation Depot, the Birmingham Venture Club, the Global Center for Medical Innovation, and the True Vine Foundation. He is a graduate of the University of Georgia and holds bachelor of science degrees in political science and chemistry.